Evidence map›Paper›PMID 33304846›Full record

ArticleFrontiers in oncology2020

CDKN2A and MTAP Are Useful Biomarkers Detectable by Droplet Digital PCR in Malignant Pleural Mesothelioma: A Potential Alternative Method in Diagnosis Compared to Fluorescence

Yuen Yee Cheng, Man Lee Yuen, Emma M Rath, Ben Johnson, Ling Zhuang, Ta-Kun Yu, Vesna Aleksova, Anthony Linton, Steven Kao, Candice Julie Clarke and 3 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.5field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Yuen Yee ChengAsbestos Diseases Research Institute, Concord, NSW, Australia.
Man Lee YuenAsbestos Diseases Research Institute, Concord, NSW, Australia.
Emma M RathGiannoulatou Laboratory, Victor Chang Cardiac Research Institute, Darlinghurst, NSW, Australia.
Ben JohnsonAsbestos Diseases Research Institute, Concord, NSW, Australia.
Ling ZhuangAsbestos Diseases Research Institute, Concord, NSW, Australia.
Ta-Kun YuAsbestos Diseases Research Institute, Concord, NSW, Australia.
Vesna AleksovaAsbestos Diseases Research Institute, Concord, NSW, Australia.
Anthony LintonAsbestos Diseases Research Institute, Concord, NSW, Australia.
Steven KaoAsbestos Diseases Research Institute, Concord, NSW, Australia.
Candice Julie ClarkeAnatomical Pathology Department, NSW Health Pathology, Concord Repatriation General Hospital, Sydney, NSW, Australia.
Brian C McCaughanSydney Cardiothoracic Surgeons, RPA Medical Centre, Sydney, NSW, Australia.
Ken TakahashiAsbestos Diseases Research Institute, Concord, NSW, Australia.
Kenneth LeeAsbestos Diseases Research Institute, Concord, NSW, Australia.
Asbestos Diseases Research Institute · AUConcord Repatriation General Hospital · AUUniversity of Sydney · AUVictor Chang Cardiac Research Institute · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe diagnosis of malignant pleural mesothelioma (MPM) can be difficult, in part due to the difficulty in distinguishing between MPM and reactive mesothelial hyperplasia (RMH). The tumor suppressor gene, CDKN2A, is frequently silenced by epigenetic mechanisms in many cancers; in the case of MPM it is mostly silenced

methodsThis study included 75 formalin fixed paraffin embedded (FFPE) MPM tissue, and 12 normal pleural tissue and 10 RMH as control. Additionally, primary MPM cell lines and normal pleural samples were used as biomarker detection controls, as established in our previous publication. All FFPE specimens were processed to isolate the DNA, that was subsequently used for ddPCR detection of CDKN2A and MTAP. FFPE samples were also analyzed by fluorescence

results95% and 82% of cases showed co-deletion of both MTAP and CDKN2A when determined by FISH and ddPCR respectively. ddPCR has a sensitivity of 72% and specificity of 100% in detecting CDKN2A homozygous loss in MPM. ddPCR also has a concordance rate of 92% with FISH in detecting homozygous loss of CDKN2A. MTAP IHC was 68% sensitive and 100% specific for detecting CDKN2A homozygous loss in MPM when these losses were determined by ddPCR.

conclusionOur study confirms that MTAP is often co-deleted with CDKN2A in MPM. Our in-house designed ddPCR assays for MTAP and CDKN2A are useful in differentiating MPM from RMH, and is highly concordant with FISH that is currently used in diagnosing MPM. ddPCR detection of these genetic losses can potentially be utilized as an alternative method in the diagnosis of MPM and for the future development of a less-invasive MPM-specific detection technique on MPM tumor tissue DNA.

Indexed as

CDKN2Adroplet digital PCRfluorescence in situ hybridizationmalignant pleural mesotheliomamethylthioadenosine phosphorylase

Identifiers

PMID33304846
PMCPMC7693432
OpenAlexW3106381609

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.